on November 9, 2006
Published online before print November 9, 2006, doi: 10.1161/01.ATV.0000252126.48375.d5
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 27, 2006
Accepted on September 3, 2006
Establishment of a High Sensitivity Plasma Assay for Human Pentraxin3 as a Marker for Unstable Angina Pectoris
Kenji Inoue ;
From the Laboratory for Systems Biology and Medicine (K.I., P.C.R., T.H., T.K.), Research Center for Advanced Science and Technology, The University of Tokyo, Japan; the Department of Cardiology (K.I.), Juntendo University Nerima Hospital, Tokyo, Japan; the Perseus Proteomics Inc (A.S., P.C.R., Y.I., M.S., K.M., H.S., I.K.), Tokyo, Japan; the Department of Cardiology (K.M., T.K., H.O., H.D.), Juntendo University School of Medicine, Tokyo, Japan; the Shin Yokohama Cardiovascular Clinic (S.M.), Kanagawa, Japan; and the Istituto Clinico Humanitas (A.M.), Italy.
* To whom correspondence should be addressed. E-mail: kodama{at}lsbm.org.
Objective--Plasma pentraxin 3 (PTX3) levels are increased in patients with acute myocardial infarction, yet its involvement in unstable angina pectoris (UAP) remains unclear. To critically evaluate the role of PTX3 in UAP, a sensitive and precise measurement of PTX3 concentration is needed.
Methods and Results--We established a high sensitive plasma ELISA assay system for the detection of PTX3 using monoclonal antibodies. The lower limit of detection of our ELISA was 0.1 ng/mL, sensitivity far greater than the current commercially available kit. Plasma samples were obtained from 162 consecutive patients treated for hypertension, hyperlipidemia, diabetes mellitus, or cardiovascular disease at a physician’s office. PTX3 was not associated with any known coronary risk factors. Additionally, we collected plasma samples from 252 consecutive subjects admitted to a university hospital for coronary artery assessment by coronary angiography. PTX3 was significantly increased in patients in whom coronary intervention was performed. We further analyzed the plasma level of PTX3 in 52 patients with effort angina (EAP) and 16 patients with UAP. Compared with the control group, PTX3 were significantly higher in the UAP group.
Conclusions--The levels of plasma PTX3 were increased in patients with arterial inflammation, especially UAP. This PTX3 detection system will be useful for the prediction of UAP.
Key words: PTX3 • hs-CRP • atherosclerosis • inflammation • acute coronary syndrome
This article has been cited by other articles:
 |
|
 |
|
  A. Doni, G. Mantovani, C. Porta, J. Tuckermann, H. M. Reichardt, A. Kleiman, M. Sironi, L. Rubino, F. Pasqualini, M. Nebuloni, et al. Cell-specific Regulation of PTX3 by Glucocorticoid Hormones in Hematopoietic and Nonhematopoietic Cells J. Biol. Chem., October 31, 2008; 283(44): 29983 - 29992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Suliman, M. I. Yilmaz, J. J. Carrero, A. R. Qureshi, M. Saglam, O. M. Ipcioglu, M. Yenicesu, M. Tong, O. Heimburger, P. Barany, et al. Novel Links between the Long Pentraxin 3, Endothelial Dysfunction, and Albuminuria in Early and Advanced Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 976 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Mallat and A. Tedgui HDL, PTX3, and Vascular Protection Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 809 - 811. [Full Text] [PDF]
|
|
|
|
 |
|
 M.E. Suliman, A.R. Qureshi, J.J. Carrero, P. Barany, M.I. Yilmaz, S. Snaedal-Jonsdottir, A. Alvestrand, O. Heimburger, B. Lindholm, and P. Stenvinkel The long pentraxin PTX-3 in prevalent hemodialysis patients: associations with comorbidities and mortality QJM, May 1, 2008; 101(5): 397 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Norata, P. Marchesi, A. Pirillo, P. Uboldi, G. Chiesa, V. Maina, C. Garlanda, A. Mantovani, and A. L. Catapano Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 925 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Salio, S. Chimenti, N. De Angelis, F. Molla, V. Maina, M. Nebuloni, F. Pasqualini, R. Latini, C. Garlanda, and A. Mantovani Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction Circulation, February 26, 2008; 117(8): 1055 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tong, J. J. Carrero, A. R. Qureshi, B. Anderstam, O. Heimburger, P. Barany, J. Axelsson, A. Alvestrand, P. Stenvinkel, B. Lindholm, et al. Plasma Pentraxin 3 in Patients with Chronic Kidney Disease: Associations with Renal Function, Protein-Energy Wasting, Cardiovascular Disease, and Mortality Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 889 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. He, B. Han, and M. Liu Long pentraxin 3 in pulmonary infection and acute lung injury Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1039 - L1049. [Abstract] [Full Text] [PDF]
|
|